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Abstract
During tumor development, loss of heterozygosity (LOH) often occurs. When LOH is preceded by an oncogene activating
mutation, the mutant allele may be further potentiated if the wild-type allele is lost or inactivated. In myeloproliferative
neoplasms (MPN) somatic acquisition of JAK2V617F may be followed by LOH resulting in loss of the wild type allele. The
occurrence of LOH in MPN and other proliferative diseases may lead to a further potentiating the mutant allele and thereby
increasing morbidity. A real time PCR based SNP profiling assay was developed and validated for LOH detection of the JAK2
region (JAK2LOH). Blood of a cohort of 12 JAK2V617F-positive patients (n = 6 25–50% and n= 6.50% JAK2V617F) and a
cohort of 81 patients suspected of MPN was stored with EDTA and subsequently used for validation. To generate germ-line
profiles, non-neoplastic formalin-fixed paraffin-embedded tissue from each patient was analyzed. Results of the SNP assay
were compared to those of an established Short Tandem Repeat (STR) assay. Both assays revealed JAK2LOH in 1/6 patients
with 25–50% JAK2V617F. In patients with .50% JAK2V617F, JAK2LOH was detected in 6/6 by the SNP assay and 5/6 patients
by the STR assay. Of the 81 patients suspected of MPN, 18 patients carried JAK2V617F. Both the SNP and STR assay
demonstrated the occurrence of JAK2LOH in 5 of them. In the 63 JAK2V617F-negative patients, no JAK2LOH was observed
by SNP and STR analyses. The presented SNP assay reliably detects JAK2LOH and is a fast and easy to perform alternative for
STR analyses. We therefore anticipate the SNP approach as a proof of principle for the development of LOH SNP-assays for
other clinically relevant LOH loci.
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Introduction
Neoplastic disorders may have a variety of underlying molecular
and cytogenetic defects. In 2005, the involvement of the
JAK2V617F somatic point mutation in myeloproliferative neo-
plasms (MPN) became apparent. JAK2V617F is caused by a G-to-
T transversion in the Janus Kinase 2 (JAK2) gene resulting in a
valine-to-phenylalanine (V-F) amino acid substitution at codon
617 [1,2,3,4]. JAK2 is a non-receptor tyrosine kinase involved in
the JAK-STAT signalling pathway [5]. The JAK2V617F mutation
apparently alters the activity of the autoinhibitory pseudokinase
JH2 domain resulting in a constitutive activation of the JAK-
STAT signalling pathway, leading to a growth factor independent
cell proliferation [6]. The diagnostic value of JAK2 mutational
analysis in MPN is now well established and has been endorsed in
the classification of haematological malignancies by the World
Health Organisation [7].
In addition to neoplasm-promoting mutations, chromosomal
imbalance may lead to loss of heterozygosity (LOH) resulting in
the deletion of tumor suppressor genes. Besides this, LOH may
lead to acquired partial uniparental disomy, excluding the wild-
type allele of a cancer-critical gene by which the effect of the
mutant oncogenic allele is further potentiated. The latter is
commonly found in combination with the JAK2V617F mutation
due to LOH of (part of) chromosome 9p [8]. A proposed
mechanism which is suggested to give rise to (partial) LOH of
chromosome 9p, and thereby JAK2V617F homozygosity, is the
mitotic recombination between homologous regions of chromo-
some 9p in a heterozygous cell [3]. It is further speculated that the
daughter cells homozygous for the JAK2V617F mutation gain
additional proliferative advantage and outcompete the
JAK2V617F heterozygous cells and homozygous wild-type JAK2
cells, thereby leading to an expansion of the JAK2V617F
homozygous subclone [3].
Polycythemia Vera (PV) patients with JAK2V617F often carry a
homozygous subclone in contrast to Essential Thrombocythemia
(ET) in which homozygosity is rare. These homozygous subclones
may predominate over time. It has been proposed that it may be
more common for PV patients to have a mutant allele burden of
.50% than for ET patients [9]. This was confirmed in a large
multicentre study during which the JAK2V617F mutational status
in patients with PV (n= 323) and ET (n= 639) was analysed.
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Of the PV patients, 67.8% was found to be JAK2V617F
heterozygous and 32.2% JAK2V617F homozygous. Only 2.2%
of ET patients were found to be JAK2V617F homozygous, whereas
40.2% was JAK2V617F-negative and 57.6% JAK2V617F hetero-
zygous [10]. Although the clinical relevance of JAK2V617F allele
burden is not yet fully understood; a correlation between disease
phenotype and the proportion of mutant alleles has been
postulated [11]. Splenomegaly, vascular events and pruritus in
PV and splenomegaly, arterial thrombosis and microvessel disease
in ET have been clinically correlated to mutant allele burdens
[12,13]. In addition to the percentage of mutant allele burden by
itself, JAK2V617F homozygosity (through JAK2LOH) is thought to
give rise to a more symptomatic myeloproliferative disease (MPD)
resulting in several clinical manifestations such as lower platelet
counts (PV), more frequent evolution into secondary myelofibrosis,
higher risks of cardiovascular events, splenomegaly and higher
leukocyte counts [10,14,15,16,17]. Besides this, JAK2V617F
homozygosity more often necessitates the use of cytoreductive
therapies [10,14]. With regard to ET, the large multicenter study
showed also that ET patients harboring homozygous JAK2V617F
mutation had a 3.9-fold higher risk of major cardiovascular events
as compared to both their heterozygous and wild type counter-
parts [10].
Quantitative real time PCR is an excellent tool for the
quantification of JAK2V617F mutant allele burden and is therefore
of clinical importance [18]. Also, determination of the LOH status
of (part of) the JAK2 region (JAK2LOH) of chromosome 9p may
be clinically relevant due to the possibility of pinpointing those
patients carrying a JAK2V617F homozygous subclone, which is
thought to give rise to a more symptomatic MPN. Several
techniques to determine LOH status have been described, such as
typing of STRs/microsatellite DNA analysis [19,20], SNP-based
pyrosequencing [19] and Affymetrix SNP microarray [8].
Although these methods provide valuable information on the
LOH status, they are often not accessible for routine molecular
laboratories –due to the necessity of expensive (pyro)sequencing or
array equipment- and often need post-PCR processing increasing
contamination risk [8,19,20]. Therefore we developed a JAK2-
LOH test for routine use based on real time amplification of SNPs
located in and adjacent to JAK2.
Materials and Methods
Ethics Statement
The presented study was performed retrospectively using
archival patient samples which were rendered anonymous before
use. The Board of Directors of the Jeroen Bosch Hospital and the
JBZ Scientific Advisory Board approved this study. Additionally,
the JBZ Scientific Advisory Board waived the need for informed
consent from the participants due to the anonymous and
retrospective nature of the study. No informed consent from the
involved patients was therefore obtained.
JAK2V617F-positive Patient Cohort
To test our SNP assay for detection of JAK2LOH, 12 patients
were selected based on JAK2V617F-positive mutational status.
This status was determined with a quantitative JAK2V617F real
time PCR based method using a PNA oligonucleotide for blocking
the wild-type allele [18]. Patients 1 to 6 carried a JAK2V617F
mutant allele burden of 25–50%, had a mean age of 7368 years
(mean 61 standard deviation) and a male:female ratio of 2:1.
Patients 7 to 12 with a mutant allele burden of .50%, rendering
JAK2LOH very likely, had an age of 7765 years (mean 61 SD)
and a male:female ratio of 1:1. EDTA blood samples used for
JAK2V617F mutational status were used for LOH analysis. A non-
neoplasmic archival formalin-fixed paraffin-embedded tissue
(FFPE-tissue) from each patient was included to establish the
germ-line profile.
Although not fully correct due to the heterogenous nature of
blood tissue, results were stated as loss of heterozygosity or
retention of heterozygosity (ROH) throughout this manuscript.
Patients Suspect of MPN Cohort
Eighty-one patients, suspected for myeloproliferative disease,
were included in this study. Inclusion was based on EDTA blood
samples collected between December 2007 – December 2009 for
JAK2V617F analyses in combination with the availability of
archived non-neoplasm related FFPE-tissue. Mean age was 60614
years (mean 61 SD) with a 1:1.3 male to female ratio. In addition
to these EDTA-blood samples used for LOH analysis, the same
cohort of patients was used to analyze non-neoplasm related
FFPE-samples from a wide variety of tissues. These samples were
originally taken for routine histological diagnostics and used in this
study to determine germ-line SNP and STR profiles.
Tissue Processing
Tissues for histological evaluation were fixed according to a
routine procedure in 0.01 mol/L buffered (0.005 mol/L disodium
hydrogen phosphate anhydrous and 0.005 mol/L sodium dihy-
drogen phosphate dihydrate, pH 7.0) 10% formalin, and pro-
cessed for paraffin embedding using a Tissue-Tek VIP 5 (Sakura,
Torrance, USA). The dehydration program consisted of 14 steps
of 1 hour under continuous agitation, pressure, vacuum, and
heating. At 40uC, two 10% formalin treatments were followed by
one 70% (v/v) ethanol treatment, two 96% ethanol treatments,
three 100% ethanol treatments, and two 100% xylene treatments.
Paraffin embedding was done at 60uC in four 100% paraffin
treatments.
Genomic DNA Extraction from FFPE-tissues
Paraffin-embedded tissues were trimmed of paraffin excess and
cut into 3 mm-thick sections. Approximately 1 to 1.5 cm2 of
sectioned tissue (a single section or short ribbons depending on the
surface per section) was put in 250 mL of digestion solution
(digestion solution with proteinase K was prepared by adding
100 mL of proteinase K solution (20 mg/mL; Roche Diagnostics
GmbH, Mannheim, Germany) and 10 mL of Tween 20 (Merck
BV, Amsterdam, The Netherlands) to 2 mL of TE buffer
(1 mmol/L EDTA, and 10 mmol/L Tris-HCl buffer, pH 8.0))
and incubated overnight at 45uC. Proteinase K was inactivated the
next day by incubation at 100uC for 15–30 minutes. Afterwards,
samples were centrifuged for 2 minutes at 14,000 rcf/G.
Genomic DNA was extracted from FFPE-tissues using the
EasyMAG NucliSens extraction system (BioMe´rieux Benelux BV,
Zaltbommel, The Netherlands). Two hundred mL digested sample,
located beneath a paraffin cap, was added to 2 mL NucliSens lysis
buffer, homogenized and incubated for 10 min. at room
temperature. The mixture was then added to the EasyMAG
vessel and 100 mL of diluted magnetic silica (50 mL silica +50 mL
ultrapure water) was subsequently added. The DNA was extracted
on the EasyMAG machine (BioMe´rieux Benelux BV, Zaltbom-
mel, The Netherlands) using the ‘‘Generic 2.0.1’’ program.
Elution was performed in 200 mL NucliSens Extraction buffer 3.
Genomic DNA Extraction from EDTA-blood
Genomic DNA was extracted from blood using the DNA blood
mini kit (Qiagen, Hilden, Germany). Two hundred mL EDTA-
SNP Based JAK2LOH Detection
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blood was added to 200 mL AL buffer, homogenized and
incubated for 10 min. at room temperature. Two hundred mL of
96% ethanol (Merck KGaA, Darmstadt, Germany) was added.
The mixture was transferred to a QIAamp column and
centrifuged for 1 min. at 8,000 rcf/G. The column was put in a
new collection tube, 500 mL AW1 buffer was added and
centrifuged for 1 min. at 8,000 rcf/G. This procedure was
repeated with 500 mL AW2 buffer and the column was centrifuged
for 1 min. at 14,000 rcf/G. To remove all ethanol from the
column it was put in a new collection tube and then subjected to a
dry spin for 1 min. at 14,000 rcf/G. Elution was performed by
adding 200 mL EL buffer, incubating for 5 min. at room
temperature followed by centrifugation for 1 min. at 8,000 rcf/G.
LOH Analysis by STR Detection
Microsatellite markers D9S1810 and D9S1681 spanned a
0.5 Mbp region of chromosome 9p, including the JAK2 gene
(figure 1A) [1]. This 0.5 Mbp region –Mbp 4.8 to 5.3- is located
within the minimal LOH region and downstream of the mitotic
recombination breakpoint as described by Kralovics and cowork-
ers [3].
The regions containing D9S1810 and D9S1681 were amplified.
Fifteen mL of mix contained 7.5 mL 26 Amplitaq Gold FAST
(Applied Biosystems, Foster City CA, USA), 0.4 mM primers
(D9S1810fw: 6FAM-TAT CAA GCA AAA CTT TTT ATT
GTG ATC ACA, D9S1810rv: GTT TCT CTT CTC TGA CAG
CAG AGC ATC C [210 bp] D9S1681fw: VIC-AGG CAG TTG
CAC AGA TAG TTA TAT ACT and D9S1681rv: GTT TCT
CAG ATT CAG CCA TGT TCC AG CAT [261 bp] (ABI); The
underlined sequences indicate the pig tail that was used to
promote adenylated products [3]) and 50 ng of isolated DNA.
DNA isolated from both EDTA-blood (tumor) and FFPE-tissue
(germline) from each patient were amplified in the same run using
a Veriti FAST Thermal Cycler (Applied Biosystems, Foster City
CA, USA) for 12 min. at 94uC followed by 10 cycles of 15 sec. at
94uC, 15 sec. at 60uC, 30 sec. at 72uC, followed by 25 cycles of
15 sec. at 89uC, 15 sec. at 60uC, 30 sec. at 72uC and a final
elongation step of 10 min. at 72uC.
Prior to capillary electrophoresis, PCR products were diluted in
ultrapure water to obtain a fluorescence signal between 400 and
8000 Fluorescent Units. Capillary electrophoresis and the
Fluorescence Unit measurement of each PCR product was
performed on a 3130 Genetic Analyzer (Applied Biosystems,
Figure 1. Distribution of Short Tandem Repeat (STR) and Single Nucleotide Polymorphism (SNP) markers on the JAK2 region, along
part of chromosome 9p. A. SNP (rs#) and STR (D9S#) marker loci within a 0.5 Mbp spanning genomic region harboring the JAK2 gene (JAK2
region). RCL1= RNA terminal phosphate cyclase-like 1 gene, JAK2= Janus Kinase 2 gene, INSL4/6= insulin-like 4 and 6 genes and RLN2= relaxin
2 gene. The arrow indicates the approximate position of JAK2V617F. B. STR and SNP results of JAK2 region of 16 patients (pt). PV = polycythemia vera,
NC = non-classified myeloproliferative neoplasm. The boxes represent all heterozygous markers. Black boxes = LOH observed for this marker, white
boxes = retention of heterozygosity observed for this marker and striped boxes = equivocal for this marker, homozygous markers are not shown.
doi:10.1371/journal.pone.0038362.g001
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Foster City CA, USA) in Hi-Di formamide together with a LIZ-
600 size marker (Applied Biosystems, Foster City CA, USA). Allele
ratios of tumor material were compared to allele ratios of germline
DNA, using Genemapper Software Version 4.0 (Applied Biosys-
tems, Foster City CA, USA).
LOH Analysis by SNP Detection
Ten predesigned TaqManH SNP Genotyping Assays (Applied
Biosystems, Foster City CA, USA) were used according to the
manufacturer’s instructions. Twenty-five mL of PCR, using the in
house made JBZ 46master mix contained, 20 mmol/L Tris-HCl,
pH 8.4, 50 mmol/L KCl, 3 mmol/L MgCl2 (prepared from 106
PCR buffer and 50 mmol/L MgCl2 solution delivered with
Platinum Taq polymerase), 0.75 U of Platinum Taq polymerase
(Invitrogen BV, Breda, The Netherlands), 4% glycerol (molecular
biology grade; Calbiochem, VWR International BV, Amsterdam,
The Netherlands), 200 mmol/L of each dNTP (Invitrogen BV),
0.5 mL of Rox reference dye (Invitrogen BV), 1.25 mL of pre-
developed assay reagent from the Assays-on-Demand SNP
genotyping products (Applied Biosystems, Foster City CA, USA)
containing two primers and two MGB TaqMan probes (59 VIC
for allele 1, 59 FAM for allele 2 and a 39 black hole quencher for
both alleles), and 11.25 mL of target DNA. Real time PCR was
performed in three different ABI Prism 7500 FAST SDS (ABI)
machines for 1 minute at 95uC, followed by 45 cycles of 3 seconds
at 95uC and 30 seconds at 60u.
Statistical Analysis SNP LOH Detection
To determine and visualize the distribution of delta Rn VIC/
FAM ratios (ratio allele 1/allele 2), box-and-whisker plots were
generated for each SNP based of the EDTA-blood samples from
the heterozygous patients –based on the germline profile generated
using the corresponding FFPE-tissues– from the patient cohort
that were negative for the JAK2V617F mutation (63/81). The box
extends from the 25th to 75th percentile of observations,
representing the interquartile range (IQR). The bars/whiskers
define the +1.5 IQR and 21.5 IQR and indicate the cut off value
for normal ratio distribution. Therefore, ratios plotted within 1.5–
36IQR are outliers and were considered equivocal with regard to
JAK2LOH status. Ratios plotted$36IQR are extremes and were
considered to be representative for JAK2LOH. All ratios with an
IQR of ,1.5 follow normal distribution and were interpreted as
JAK2 ROH.
Leukocyte, Thrombocyte and Erythrocyte Counts
Leukocyte, thrombocyte and erythrocyte counts were routinely
determined directly after sampling by the SE9500/XE2100
(Goffin Meyvis, Etten-Leur, The Netherlands) analyzers.
The cell counts were firstly judged for fit to the normal
distribution by using stem-and-leaf plots and quantile-quantile
plots. As our data did not follow a normal distribution, Mann-
Whitney U tests were performed for comparison of the cell counts
between the JAK2ROH and JAK2LOH group.
Results
STR and SNP Selection
STRs D9S1810 and D9S1681 span the 0.5 Mbp minimal
9pLOH region, incorporating the JAK2 gene (figure 1A), and have
been used before by Kralovics and coworkers to investigate
9pLOH [3].
Ten SNPs were selected in silico using SNP browser software
Version 4.0 (ABI). Selection was based on allele frequencies of
around 0.5 and location within or near the JAK2 gene covering the
0.5 Mbp 9p region in between D9S1810 and D9S1681 (figure 1A
and table 1). For real time PCR based amplification and SNP
detection, TaqManH SNP Genotyping Assays from Applied
Biosystems were used. During technical validation, one (SNP
rs7862852) of the ten SNP assays showed cross reactivity of the
FAM MGB probe with allele 1 (VIC) and poor amplification of
allele 2 (FAM) in the presence of allele 1. Therefore, allele calling
could not be performed and TaqManH SNP Genotyping Assay for
rs7862852 was excluded from LOH analyses. The other 9 SNP
assays generated reliable allele calls and were therefore suitable for
inclusion in the JAK2LOH panel (figure 1A and table 1).
Patient Cohorts
Two patient cohorts were used in this study: a cohort of 12
JAK2V617F-positive patients and a cohort of 81 patients suspect of
MPN.
FAM/VIC ratios were plotted per SNP in a scatterplot.
Figure 2A shows the scatterplot of SNP rs3780378 for paired
paraffin and blood samples of all patients in both cohorts. The
data obtained for SNP rs3780378 are representative for the entire
SNP panel. Four clusters –homozygous VIC, homozygous FAM,
heterozygous FAM/VIC ABI7500FAST machine 1 and 2 and
heterozygous FAM/VIC ABI7500FAST machine 3- were ob-
served. FAM/VIC ratios plotted outside these clusters were
considered to represent LOH or to be equivocal as was statistically
determined using box-and-whisker plots (figure 2B). In addition, a
FAM/VIC ratio of a blood sample from a heterozygous patient
present in a homozygous cluster was considered to represent
LOH.
Statistical Analysis SNP LOH Detection
Box-and-whisker plots were generated, based on the VIC/FAM
ratios from EDTA-blood samples of all heterozygous patients from
the patient cohort suspect of MPN that were negative for the
JAK2V617F mutation (63/81), for all SNP assays (data not shown).
Table 1. Panel of selected Single Nucleotide Polymorphisms
(SNPs).
SNP-ID
(hCV)
SNP-ID
(rs)
Base
(9p) SNP Minor allele frequency
CEU CHB JPT YRI
29340651 7869592 4,866,301 T/C 0.46 0.40 0.35 0.47
2008226 10974837 4,885,391 A/G 0.48 0.44 0.49 0.46
657006 7853852 4,879,126 C/G 0.46 0.49 0.47 0.49
34291956* 7862852 4,962,398 C/T 0.45 0.46 0.35 0.33
2008287 7849191 4,978,761 C/T 0.50 0.48 0.41 0.19
29340600 7857730 5,074,049 T/G 0.47 0.42 0.45 0.11
27480690 3780378 5,102,288 T/C 0.47 0.46 0.50 0.45
16225021 2381195 5,135,887 T/C 0.49 NA NA NA
28001006 2224572 5,278,707 A/T 0.37 0.43 0.49 0.44
31941380 10815188 5,344,681 T/C 0.40 0.41 0.48 0.30
SNP-ID (hCV) = Celera SNP ID. SNP-ID (rs) = reference SNP ID number. Base
(9p) = the nucleotide position on chromosome 9(p). The particular nucleotide
variation is referenced in ‘‘SNP’’-column. Minor allele frequencies are indicated
for different populations: CEU, CEPH (Centre d’Etude du Polymorphisme
Humain) from Utah; CHB, Chinese from Beijing; JPT, Japanse from Tokyo and
YRI, Yoruba from Ibadan Nigeria.
*SNP rs7862852 is excluded from the panel of recommended SNPs. NA = not
applicable.
doi:10.1371/journal.pone.0038362.t001
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Data from the JAK2V617F-positive cohort samples that were
selected based on their mutant allele burdens of 25–50% and
.50% JAK2V617F and therefore more likely to contain
JAK2LOH were not included. Inclusion of JAK2V617F-positives
would lead to a larger variety in VIC/FAM ratios and therefore a
biased IQR. This would influence outlier (equivocal) and extreme
(JAK2LOH) calling. VIC/FAM ratios generated with the
JAK2V617F-positive patients were called (JAK2ROH, equivocal
or JAK2LOH) using the measured IQRs of the JAK2V617F-
negative patients from the patient cohort.
One representative box-and-whisker plot generated using SNP
rs3780378 is shown in figure 2B. Based on these calculations,
patient 15, 39, 44 and 61 were found to be extremes (JAK2LOH)
as additionally presented in figure 1B.
JAK2V617F-positive Patient Cohort
The cohort of 12 JAK2V617F-positive patients was composed
with samples containing mutant allele burdens of 25–50%
(patients 1–6) and burdens above 50% (patients 7–12). The results
of STR vs. SNP LOH analyses are summarized in cross table 2.
Patients 1, 2 and 4 showed STR and SNP results consistent with
ROH of the JAK2 region. Patients 5, 7, 9, 10, 11 and 12 showed
JAK2LOH in both assays. In patient 3 discrepant results were
found in STR vs. SNP testing (ROH/LOH). The STR assay
results were indicative of JAK2ROH, whilst the SNP profile
revealed different results among the various SNPs. SNPs
rs7857730 and rs3780378 revealed the presence of one of the
two germ line alleles, while the 3 other informative SNPs were
found to be heterozygous. Overall results for patient 5 were
ROH/ROH. However, SNP rs7869592 result was found to be
equivocal, while the 4 other SNPs showed ROH and the
remaining 4 SNPs were non-informative (table 2). LOH of the
JAK2 region was additionally shown in patient 8 using the SNP
assay while STR results were non-informative (figure 1B and
table 3). In patient 4, SNP rs7869592 was heterozygous but was
found to be equivocal, STR results were indicative for ROH.
Patients Suspect of MPN Cohort
Eighteen patients harbored the JAK2V617F mutation, whereas
63 patients did not. The JAK2LOH/ROH results for both groups,
as generated by SNP and STR analysis, are summarized in cross
table 4. Equivocal and non-informative results are summarized in
table 3.
Within this cohort, 64 patients were found to generate ROH
results in both assays (ROH/ROH). Patients 15, 39, 41, 44 and
61–all JAK2V617F-positive- yielded results indicative of JAK2-
LOH in both assays (figure 1B). Patient 68 displayed JAK2LOH in
the SNP assay, whilst the STR assay was non-informative due to
homozygosity for both markers. Patient 38 yielded equivocal
results using SNP rs7869592, while SNP rs10815188 and STR
D9S1810 results were indicative of ROH. Patients 13, 20, 22, 24,
Figure 2. Visualization of FAM/VIC ratios generated by representative SNP rs3780378 A. Scatterplot of SNP rs3780378 analyses of paired
EDTA-blood and formalin-fixed paraffin-embedded (FFPE)-tissues of 93 patients (12 patients from JAK2V617F-positive cohort and 81 sample pairs
from the MPN suspect patient cohort). X-axis: Delta Rn VIC (T = Thymine), Y-axis: Delta Rn FAM (C = Cytosine). White squares (bl-M1&2) = EDTA-
blood samples amplified using ABI7500FAST machines 1 and 2, grey squares (bl-M3) = EDTA-blood samples amplified using ABI7500FAST machine 3,
white triangles (par-M1&2) = FFPE-tissue samples amplified using ABI7500FAST machines 1 and 2 and grey triangles (par-M3) = FFPE-tissue samples
amplified using ABI7500FAST machine 3. B. Representative box-and-whisker plot generated using the SNP rs3780378 VIC/FAM ratios of the EDTA-
blood samples of all heterozygous patients from the patient cohort analyzed with ABI7500FAST machines 1 and 2. Stars represent extremes (.36
IQR = JAK2LOH).
doi:10.1371/journal.pone.0038362.g002
Table 2. Cross table of JAK2 region loss of heterozygosity
results of the JAK2V617F-positive patient cohort, generated by
the Short Tandem Repeat (STR) assay and the Single
Nucleotide Polymorphism (SNP) based assay.
SNP JAK2 LOH assay
STR JAK2 LOH assay JAK2LOH JAK2ROH Total
JAK2LOH 6A 0 6
JAK2ROH 1B 3C 4
Total 7 3 10
A = patient (pt) 5, 7, 9, 10, 11 and 12,
B = pt 3*, C = pt 1, 2 and 6**.
*LOH observed for a small region of the JAK2 gene, in proximity of the
JAK2V617F codon.
**rs7869592 equivocal, other 4 SNPs indicative of ROH.
JAK2LOH = loss of heterozygosity on the JAK2 region, JAK2ROH = retention of
heterozygosity on the JAK2 region.
doi:10.1371/journal.pone.0038362.t002
SNP Based JAK2LOH Detection
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25, 59 and 69 were found to be non-informative with the STR
assay, while SNP analysis showed JAK2ROH. SNP profiles of
patients 32, 55 and 93 were considered non-informative due to an
incomplete SNP profile (4, 7 and 5 out of 10 SNPs, respectively) of
the reference FFPE-sample (due to low DNA loads) in combina-
tion with being homozygous for all interpretable SNPs. These
patients showed JAK2ROH in the STR assay (table 3).
Leukocyte, Thrombocyte and Erythrocyte Counts
Mean cell counts (61 SD), due to the retrospective nature of
this study available for 24 JAK2V617F-positive patients, for the
JAK2LOH (n=12 [including patient 3]) vs. the JAK2ROH
(n=12) group were: 18.7614.96109 vs. 10.664.16109 leuko-
cytes/L, 46062666109 vs. 68863906109 thrombocytes/L and
6.0061.3861012 vs. 4.5861.0561012 erythrocytes/L.
Leukocyte and erythrocyte counts were significantly higher (p-
value = 0.045 and 0.007) in the JAK2LOH group than in the
JAK2ROH group. Thrombocyte counts did not differ significantly
between the two groups (p-value = 0.068).
Discussion
We have developed a SNP based assay, which is easy to perform
and reliably detects JAK2LOH. Ten SNPs located on 9p within
the JAK2 region were selected in silico based on incidence around
0.5 in Caucasian (CEU, CEPH (Centre d’Etude du Polymor-
phisme Humain) from Utah), Chinese (CHB, Chinese from
Beijing), Japanese (JPT, Japanese from Tokyo) and African (YRI,
Yoruba from Ibadan Nigeria) populations. Technical validation of
the accompanying SNP assays revealed that nine SNP assays
fulfilled the criteria for inclusion -clear distinction of homo2/
heterozygous clusters, allele frequency in investigated population
around 0.5 (data not shown) and sufficient sensitivity- in the
JAK2LOH/ROH panel. SNP rs7862852 was excluded from the
recommended panel of SNP markers due to poor performance.
A second technical issue with regard to the SNP assay was
encountered when three different ABI7500FAST systems were
employed. Two distinct groups of homozygotes were observed for
machine 1&2 vs. machine 3 (figure 2). For each ABI7500FAST
system all dyes employed (including FAM and VIC) are calibrated
individually once every three months in our diagnostic setting.
Variations introduced during such a calibration are inevitable as
well as those caused by differences in light intensity generated by
the integrated lamp which is replaced after 2,000 burning hours.
These technical issues may induce inter-machine variability. To
prevent misinterpretation of JAK2LOH/ROH status, we recom-
mend analyzing EDTA-blood samples and corresponding FFPE-
tissue on one ABI7500FAST as a control within the same run.
When interpreting the results with regard to JAK2LOH and
ROH status, it should be taken into account that blood is a
heterogeneous tissue. The demonstrated technique will therefore
only detect JAK2LOH in those patients where the homozygous
subclone is abundant enough. The assess the range in which
homozygous subclones are abundant enough to be detected by the
SNP assay, a serial dilution of DNA of a healthy homozygous
patient and DNA of a healthy heterozygous patient (for SNP
rs7849191) was made and tested. The 5%, 10% and $20% (20,
30, 40 and 50%) dilutions yielded results that were interpreted
using the generated cut off values as ‘‘ROH’’, equivocal with
regard to ‘‘LOH status’’ and indicative of ‘‘LOH’’, respectively
(results not shown). Indicating a sensitivity of at least 20%
homozygous cells in a heterozygous background using represen-
tative SNP rs7849191.
With regard to the interpretation of the STR results, difficulties
were encountered when analyzing the data automatically. When
allelic ratios were called by the Genemapper Software Version 4.0
(ABI), LOH/ROH calls were found to be doubtful in cases where
DNA loads were aberrant -low loads observed in several FFPE-
tissues and high loads in some blood samples-. The software did
not take into account that signals .8,000 or with very low
fluorescent units negatively influenced allelic ratios, resulting in
false LOH calls. Therefore, an additional manual analysis of all
STR results was performed to determine STR JAK2 status. To
assure that manual interpretation was objective, an LOH index
was calculated. This index was calculated by determining the
intensity of the PCR products, which was used to calculate the
intensity ratio between the peaks of both alleles in the tumor
sample. Dividing this ratio by the same ratio found in the normal
tissue yielded the LOH index. When this LOH index was below
0.75, this was interpreted as LOH, whereas an LOH index of
.0.75 was interpreted as ROH.
Considering the STR assay to be the golden standard, the SNP
assay’s sensitivity and negative predictive value were 100% for
both the JAK2V617F-positive patient cohort and the patients
suspect of MPN cohort. Positive predictive values of the SNP assay
were 85.7% and 100% and the specificity was 80% and 100% in
the respective cohorts. Patient 3 showed no signs of JAK2LOH
Table 3. Cross table of equivocal and non-informative results,
generated by the Short Tandem Repeat (STR) assay and the
Single Nucleotide Polymorphism (SNP) based assay.
SNP JAK2LOH assay
STR JAK2LOH
assay JAK2LOH JAK2ROH
Non-
informative Equivocal Total
JAK2LOH NA NA 0 0 0
JAK2ROH NA NA 3E 2F 5
Non-informative 2G 7H 0 0 9
Equivocal 0 0 0 0 0
Total 2 7 3 2 14
E = pt 32, 55 and 93,
F = pt 4 and 38,
G = pt 8 and 68,
H = pt 13, 20, 22, 24, 25, 59 and 69.
JAK2LOH = loss of heterozygosity on the JAK2 region, JAK2ROH = retention of
heterozygosity on the JAK2 region. Results were indicated as non-informative
due to homozygous STR/SNP profiles in the formalin-fixed paraffin-embedded
tissues. NA = not applicable.
doi:10.1371/journal.pone.0038362.t003
Table 4. Cross table of JAK2 region loss of heterozygosity
results of the patients suspect of MPN cohort, generated by
the Short Tandem Repeat (STR) assay and the Single
Nucleotide Polymorphism (SNP) based assay.
SNP JAK2LOH assay
STR JAK2LOH assay JAK2LOH JAK2ROH Total
JAK2LOH 5D 0 5
JAK2ROH 0 64 64
Total 5 64 69
D = patients 15, 39, 41, 44 and 61.
JAK2LOH = loss of heterozygosity on the JAK2 region, JAK2ROH = retention of
heterozygosity on the JAK2 region. MPN = myeloproliferative neoplasm.
doi:10.1371/journal.pone.0038362.t004
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using the STR assay. Analyses of SNPs close to both STR loci also
showed ROH. However, two SNPs in between the two STR loci
in relative close proximity to JAK2V617F (rs7857730 and
rs3780378 10–15 Kb and 35–50 Kb downstream, resp.) were
not indicative of ROH. Rs7857730 and rs3780378 clearly showed
JAK2LOH. It is likely that a small deletion, point mutation or a
small recombination event around rs7857730 and rs3780378
accounts for these observations.
Of the 81 patients in the patient cohort suspect of MPN,
JAK2LOH was found in 6 patients (7%), i.e. one-third (6/18) of
the JAK2V617F-positive patients. Amongst the JAK2V617F-
negative patients, no cases of JAK2LOH were found.
That JAK2LOH was found in 2/5 patients from the
JAK2V617F-positive cohort with a JAK2V617F mutant allele
burden below 50% is in line with the findings of Scott and
coworkers, describing that a large number of PV patients harbor
homozygous subclones, which may predominate over time [9].
Moreover, it indicates that next to JAK2V617F quantification the
determination of JAK2LOH status provides additional information
and could be of value.
In patient 4, rs7869592 was the only informative SNP and was
found to be equivocal. Patient 38–positive for JAK2V617F- yielded
an equivocal result for SNP rs7869592, SNP rs10815188 and
D9S1681 were representative of JAK2ROH. All other markers
were non-informative due to homozygosity. The overall result was
therefore concluded to be equivocal for patients 4 and 38
(figure 1B, table 3). Patient 44 yielded results indicative of
JAK2LOH for D9S1810 and 8/9 SNPs, whereas D9S1681 and
rs10815188 yielded results indicative of JAK2ROH (figure 1B).
The mechanism behind this observation is unclear. A possible
explanation could be an inversion of the D9S1681/rs2224572
locus that might have arisen during the process of recombination.
In patient 61, the result from marker D9S1681 was indicative of
JAK2LOH, whereas D9S1810 yielded a JAK2ROH result. Results
from 6/9 SNPs were indicative of JAK2LOH, the result from one
SNP was equivocal (figure 1B). We presume that this aberrant
observation is due to mutation of the concerning JAK2 region.
In both patient cohorts the STR assay resulted in a total of 9
non-informative homozygous profiles, of which patient 8 and 68
were found in the SNP assay to harbor cells with JAK2LOH.
Analysis of the cohorts using the SNP assay resulted in 3 non-
informative homozygous profiles, of which the STR results were
representative of JAK2ROH. Thus the SNP assay has a higher
success rate than the STR assay in this population. Caution is
however advised when handling samples with low DNA loads.
Additionally, the SNP assay provides more detailed information
with regard to ROH/LOH status of the JAK2 gene and
surrounding loci.
In total, in 14 patients the SNP assay results were indicative of
JAK2LOH (including patient 3, where a small part of the JAK2
region was affected; figure 1B and table 2) with an overall mean
age of 7467 years and a male:female ratio of 1.00:0.75. The 30
JAK2V617F-positive patients consisted of 8 PV patients, 7 ET
patients, 1 IMF patient and 14 patients with a non-classified
MPN. The occurrence of JAK2LOH amongst the different disease
phenotypes was: PV 100% (n=8), ET 0% (n= 7), IMF 0% (n= 1)
and non-classified MPN 42.9% (n= 14). Similar distributions were
previously found showing that JAK2LOH is a common event in
PV and the contrary, is very rare in ET and IMF
[9,10,11,12,13,14,15,16,17]. The fact that within the group of
JAK2V617F-positive patients, leukocyte and erythrocyte counts
were significantly higher in patients with JAK2LOH in comparison
to patients with JAK2ROH may indicate a more symptomatic
disease in the first group. This is in line with previous findings
where the higher mutant allele burden was found to be correlated
to lower platelet counts, higher incidence of splenomegaly and
larger spleen size, cytoreductive therapy needed in a greater
number of patients and higher white blood cell counts in PV and
ET. A higher incidence of thrombotic events is also observed in
PV and ET, particularly with mutant allele burdens above 50%.
Significantly higher chances of fibrotic transformation have been
observed in both PV and ET [10,14,15,16,17]. Additionally, MPN
in patients 10 and 44 with JAK2LOH evolved into leukemia;
patient 10 suffered from AML and patient 44 suffered from B-
CLL in combination with AML and subsequently deceased. No
leukemic transformation was observed in the JAK2ROH group.
Because the SNP assay relies on real time PCR, the technique is
fast, easy to perform and requires less hands-on time in
comparison to STR analysis –1.5 hours vs. 3 hours-. In addition,
the SNP assay does not require the use of expensive sequencing
equipment, is therefore more easily accessible for smaller routine
molecular diagnostic laboratories. No post-PCR processing is
necessary, diminishing contamination risks. Besides the current
application of JAK2LOH testing, the demonstrated SNP technique
may prove useful as a diagnostic strategy for determination of
LOH status in other neoplastic entities such as 18q LOH in
colorectal cancer [21,22,23]. In addition to the in this study
described use of archival FFPE-tissues to generate germline SNP
profiles, real time PCR based SNP profiling was described to be
suitable in combination with buccal swabs [24], providing more-
easy-to-obtain reference material.
In conclusion, we have developed a novel and easily accessible
SNP based assay to reliably determine JAK2LOH status.
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